News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

APOXIS S.A. Acquires Worldwide Rights For Novel Anti-Cancer Compound From Astellas Pharma Inc.


12/15/2005 12:40:51 PM

Apoxis SA, a Swiss biopharmaceutical company developing oncology and immunology products, today announced it has acquired exclusive worldwide development and marketing rights for anti-cancer compound FK866 from Astellas Pharma GmbH, Munich, Germany. Apoxis intends to initiate a series of phase II studies of the product, re-named as APO866, in 2006.


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES